At Emerald Health Pharmaceuticals, we are passionate about what matters most—patients.
We combine decades of life science and drug development experience with industry-leading expertise in cannabinoid science into the creation of our novel molecules. With patients at the core of our mission, Emerald Health Pharmaceuticals is focused on providing new and improved healthcare solutions based in cannabinoid science, centered around patient outcomes.
Our work in cannabinoid science has been well-received by the scientific community and published by independent, credible scientific journals. Click the link below to review the advances we have made in the development of new chemical entities for the treatment of neurogenerative, autoimmune and CNS diseases.
Current Clinical Trials
Currently, we are preparing to enter into a Phase 2 clinical study of EHP-101 for the treatment of Multiple Sclerosis and Systemic Sclerosis.